Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix.
Between April 1979 and January 1982, 331 patients were included in a study to establish whether misonidazole (MISO) had any effect as an adjuvant to radiotherapy in the treatment of squamous cell carcinoma of the uterine cervix (FIGO Stage IIb, III, and IVa). Patients were randomized to receive either MISO (12 g/m2 applied within 6 weeks) or placebo. This was given in conjunction with each institution's normal radiotherapy schedule and thus varied with regard to external and intracavitary irradiation. The analysis was performed based on patients' status at January 1986, with all patients observed for at least 4 years. One hundred and sixty-four patients received MISO and 167 placebo. Compliance to radiotherapy was good and MISO was well tolerated. The overall rates for MISO vs. placebo were as follows: local tumour control, 50 vs. 54%; disease-free survival, 47 vs. 46%, and crude survival, 39 vs. 45%. A similar lack of MISO effect was found in the individual stages. However, patients in all stages with hemoglobin concentrations below 7 mmol/l had a significantly lower local control probability (overall 24 vs. 47%), whereas the incidence of distant metastases was unaffected. We conclude that the addition of MISO did not influence the radiation response in advanced uterine carcinoma. The reasons for this ineffectiveness are yet to be clarified.
Overgaard
J
J
Danish Cancer Society, Dept. of Experimental Clinical Oncology, Aarhus.
Bentzen
S M
SM
Kolstad
P
P
Kjoerstad
K
K
Davy
M
M
Bertelsen
K
K
Mäntyla
M
M
Frankendal
B
B
Skryten
A
A
Löftquist
I
I
D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008920:Misonidazole / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D011897:Random Allocation; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*
D008920:Misonidazole